• for investors
  • for entrepreneurs
  • companies
  • news
  • about us

Calyxha’s novel therapies

Sep 9, 2020

Calyxha Biotechnologies GmbH is developing novel therapies targeting #neurodegeneration, the underlying cause of major human diseases, such as Parkinson’s disease.

https://www.calyxha.com/

 

_Latest News

Macomics and Ono Pharma partner to develop macrophage-targeting antibody therapy

Macomics and Ono Pharma partner to develop macrophage-targeting antibody therapy

March 23, 2023

Spiral completes new financing and initiates Phase 2 Trial in Ménière’s disease

Spiral completes new financing and initiates Phase 2 Trial in Ménière’s disease

January 17, 2023

2022 Annual Biotech Report – LifeLink Ventures

2022 Annual Biotech Report – LifeLink Ventures

January 5, 2023

Chameleon Biosciences named Immunomodulatory Solution of the Year

Chameleon Biosciences named Immunomodulatory Solution of the Year

November 15, 2022

Ochre Bio brings together an incredible Scientific Strategy Board

Ochre Bio brings together an incredible Scientific Strategy Board

October 28, 2022

Accure Therapeutics signs licensing agreement with Oculis

Accure Therapeutics signs licensing agreement with Oculis

March 3, 2022

2021 Annual Biotech Report – LifeLink Ventures

2021 Annual Biotech Report – LifeLink Ventures

December 22, 2021

A new and exciting partnership between CEBINA and the multinational Evotec

A new and exciting partnership between CEBINA and the multinational Evotec

June 16, 2021

Coronavirus – LifeLink Newsletter IV

Coronavirus – LifeLink Newsletter IV

March 18, 2021

contact us

Barcelona Spain

  • Follow
  • Follow

navigate

  • for investors
  • for entrepreneurs
  • companies
  • news
  • about us

legal conditions

  • Legal notice
  • Cookies policy
  • Privacy policy
  • Credits
This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies. For more information on cookies check:
OkCookies policyPrivacy policy
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
  • home
  • for investors
  • for entrepreneurs
  • companies
  • news
  • about us